Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UXT antisense RNA 1 (UXT-AS1)
- Target
- UXT-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Natural antisense transcript, SINEUP (when acting as translation activator in specific contexts, inferred from related lncRNAs[3][4])
01
Overview
UXT antisense RNA 1 (UXT-AS1) is a long non-coding RNA (lncRNA) that is transcribed antisense to the protein-coding gene UXT. Like other natural antisense lncRNAs, UXT-AS1 does not encode a protein but may regulate gene expression post-transcriptionally. UXT-AS1 has been found to be significantly upregulated in pancreatic ductal adenocarcinoma and acts as an oncogene in colorectal cancer. Elevated expression of UXT-AS1 is associated with poor prognosis in pancreatic cancer, potentially by modulating immune-related pathways, cell adhesion, and nuclear factor kappa beta signaling. Computational analyses have linked UXT-AS1 transcriptomic effects to drugs such as quipazine and terazosin, but no direct mechanism of drug/lincRNA binding is known. UXT-AS1 can serve as a prognostic biomarker in certain cancers but is not currently considered a classical drug target such as a receptor or enzyme[2][3][4].
- Other names
- UXT-AS1UXT antisense RNA 1
02
Mechanism of action
Not a protein or classical drug target, but drugs (quipazine, terazosin) identified as having inverse expression signatures relevant to UXT-AS1 activity/associated transcriptomic profile in cancer[2]
03
Biological functions
Regulation of gene expression (post-transcriptional)Potential oncogenic role in cancer (acts as an oncogene in colorectal cancer and pancreatic ductal adenocarcinoma[2])Involvement in immune signaling regulation (e.g., nuclear factor kappa beta, T cell receptor signaling[2])Participation in cell adhesion and multiple immune-related biological processes[2]
04
Disease associations
CancerSpecifically implicated in pancreatic ductal adenocarcinoma prognosis[2]Implicated as an oncogene in colorectal cancer[2]
05
Safety considerations
No direct therapeutic targeting or drug safety profile established, as UXT-AS1 is not a well-validated therapeutic target.As a biomarker, typical concerns are assay sensitivity/specificity and clinical validation.
06
Interacting drugs
Quipazine
1 more in the full profile.
07
Biomarkers
UXT-AS1 expression as a prognostic biomarker in pancreatic ductal adenocarcinoma[2]
Beyond the preview
Go deeper on UXT antisense RNA 1 (UXT-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UXT antisense RNA 1 (UXT-AS1).